Trial intelligence / Profile preview

Teclistamab versus investigator's choice PVd or Kd in relapsed or refractory multiple myeloma

ISRCTN80324107Phase 3Active, not recruiting

Sponsor

Janssen Pharmaceutical

Start

Mar 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules